Copyright 2024
| PMID | Allele | Disease | Population | Drug Names | SNP | Class | Sentence |
|---|---|---|---|---|---|---|---|
| 8937542 | HUMAN LEUKOCYTE ANTIGEN (HUMAN LEUKOCYTE ANTIGEN) | myelopathy | NA | NA | NA | unclassified | |
| in htlv-1 associated myelopathy/tropical spastic paraparesis (ham/tsp), we correlated human leukocyte antigen (hla) haplotypes to the fine specificities of intrathecally synthesized igg antibodies against htlv-1. | |||||||
| 20483367 | HUMAN LEUKOCYTE ANTIGEN (HUMAN LEUKOCYTE ANTIGEN) | spastic paraparesis | Peruvian | NA | NA | unclassified | |
| role of killer cell immunoglobulin-like receptor gene content and human leukocyte antigen-c group in susceptibility to human t-lymphotropic virus 1-associated myelopathy/tropical spastic paraparesis in peru. | |||||||
| 20483367 | HUMAN LEUKOCYTE ANTIGEN (HUMAN LEUKOCYTE ANTIGEN) | myelopathy | Peruvian | NA | NA | unclassified | |
| role of killer cell immunoglobulin-like receptor gene content and human leukocyte antigen-c group in susceptibility to human t-lymphotropic virus 1-associated myelopathy/tropical spastic paraparesis in peru. | |||||||
| 32883310 | HLA-B*35 | spastic paraparesis | NA | NA | NA | unclassified | |
| hla-b*35 as a new marker for susceptibility to human t-cell lymphotropic virus type 1 (htlv-1) associated myelopathy/tropical spastic paraparesis (ham/tsp) in patients living in argentina. | |||||||
| 32883310 | HLA-B*35 | myelopathy | NA | NA | NA | unclassified | |
| hla-b*35 as a new marker for susceptibility to human t-cell lymphotropic virus type 1 (htlv-1) associated myelopathy/tropical spastic paraparesis (ham/tsp) in patients living in argentina. | |||||||
| 7701581 | HLA IDENTICAL (HLA-IDENTICAL) | gaucher disease | NA | NA | NA | unclassified | |
| the data suggest that in advanced gaucher disease bmt still may be a treatment of choice if an hla-identical related or unrelated donor is available. | |||||||
| 15952302 | HLA MATCHED (HLA-MATCHED) | gaucher disease | NA | NA | NA | unclassified | |
| in this study, a patient with type i gaucher disease was treated by allogeneic bmt from hla-matched sibling donor. | |||||||
| 20038335 | HLA-DPB1 (HLA-DPB1) | gaucher disease | NA | NA | NA | only_studied | |
| nineteen ttg1a binding proteins, including homo sapiens major histocompatibility complex, class ii dp beta 1 (hla-dpb1), homo sapiens ribosomal protein l30 (rpl30), homo sapiens nucleophosmin homo sapiens nucleobindin 2 (nucb2), homo sapiens ash2, variant gaucher disease and variant metachromatic leukodystrophy, morf4l1, homo sapiens ubiquitin-conjugating enzyme e2l3 (ube2l3), apoa1, homo sapiens lectin, and galectin 1, were identified. | |||||||
| 20038335 | HLA-DPB1 (HLA-DPB1) | metachromatic leukodystrophy | NA | NA | NA | only_studied | |
| nineteen ttg1a binding proteins, including homo sapiens major histocompatibility complex, class ii dp beta 1 (hla-dpb1), homo sapiens ribosomal protein l30 (rpl30), homo sapiens nucleophosmin homo sapiens nucleobindin 2 (nucb2), homo sapiens ash2, variant gaucher disease and variant metachromatic leukodystrophy, morf4l1, homo sapiens ubiquitin-conjugating enzyme e2l3 (ube2l3), apoa1, homo sapiens lectin, and galectin 1, were identified. | |||||||
| 23266622 | HLA-CLASS I (HLA CLASS II) | gaucher disease | NA | NA | NA | unclassified | |
| kir genes and hla class i ligands in gaucher disease. | |||||||
Copyright 2024